These Stocks Have Explosive Capabilities

HENDERSON, NV / ACCESSWIRE / October 18, 2018 / Several stocks have caught our eye this week, which we have highlighted below.Propanc Biopharma, Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors, is the one we’re most excited about. PPCB had a massive run from late August through early September exploding from $0.0039 - a high of $0.288 which represented a gain of over 7000%.The company also has a 52 week high of $0.77.If this is your first time hearing about PPCB start doing your own due diligence immediately.The FDA granted PPCB Orphan Drug Designation for its lead product PRP for the treatment of pancreatic cancer. This qualifies the Company for seven-year FDA-administered market Orphan Drug Exclusivity (ODE), tax credits of up to 50% of R&D costs, potential for R&D grants, waived FDA fees, protocol assistance and possible clinical trial tax incentives if conducted in the U.S.

The company is also very close to its first-in-human studies.

The stock found support recently and has been on the upswing, this week is a perfect time to learn more about this stock as it looks possibly set for its next major run.

A few companies to watch include:Propanc Biopharma, Inc. (PPCB), Aurora Cannabis, Inc. (ACBFF), MedMen Enterprises, Inc. (MMNFF), Puration, Inc. (PURA), and CV Sciences, Inc. (CVSI).

Propanc Biopharma, Inc. (PPCB)

Market Cap: $13.73M Share Price: $0.077

Propanc Biopharma, Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, just announced initiation of European (EP) validation of its lead patent in most major commercial markets in Europe. EP validation is the process of converting a single granted European patent application into a national patent in one or more contracting member and extension states of the European Patent Convention.

The Company's lead patent, which describes a pharmaceutical composition for treating cancer, is currently undergoing validation in 14 European countries - Belgium, Czech Republic, Denmark, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey and the United Kingdom. Once validated, the Company will have the rights associated with a granted patent in each of these 14 European countries.

Aurora Cannabis, Inc. (ACBFF)

Market Cap: $10.79B Share Price: $11.23

The company released fiscal fourth-quarter earnings and confirmed its intention to list stock on a "senior" U.S. exchange such as the Nasdaq or the New York Stock Exchange.

Further to this on Friday, October 5, the company filed a Form-40 with the intent of registering its securities on the New York Stock Exchange. Aurora could join the ranks of a growing number of cannabis companies choosing to list on major exchanges in the US. Late last month, Canaccord Genuity raised its price target for Aurora Cannabis to 13 Canadian dollars from 11 Canadian dollars.

Aurora Chief Executive Terry Booth said, "This listing provides access to a broader investor audience who gain the opportunity to participate in our continued success."

MedMen Enterprises, Inc. (MMNFF)

Market Cap: $443.18M Share Price: $6.26

MedMen Enterprises, Inc. (MMNFF) and Chicago-based PharmaCann LLC have provided additional detail related to the binding letter of intent for MedMen to acquire all of PharmaCann’s outstanding equity interests. Under the terms of the Agreement, PharmaCann units will be exchanged for equity interests which will include the right to receive the Company’s Class B Subordinate Voting Shares, and which on a pro-forma basis will equal 25% of the then fully-diluted outstanding shares of the Company (calculated based on the treasury stock method) upon the closing of the transaction. The total transaction was valued at $682 million (USD) based on the closing price of the Company’s Class B Subordinate Voting Shares on October 9, 2018 (such value being subject to change based on the daily closing price of the Company). No change of control to the Company will result upon the Closing. The Shares are expected to be subject to lock up agreements for a period of between 6-12 months.

Puration, Inc. (PURA)

Market Cap: $10.15M Share Price: $0.20

Puration, Inc. (PURA) released an online management presentation to provide more detail on its corporate restructuring to concentrate resources on its rapidly expanding cannabis infused beverage business. The presentation includes details on the recently announced spinoff of its cannabis cultivation business and the pending dividend distribution of spinoff stock. The presentation also includes details on the company's current two cannabis infused beverages and the recently announced letter of intent to acquire a company with a third cannabis sector beverage. The presentation highlights the company's overall strategy to optimize the movement of major brand name beverage industry players into the cannabis sector in addition to reporting recent interest shown by some brand name players into Puration's experience in the cannabis infused beverage sector.

CV Sciences, Inc. (CVSI)

Market Cap: $534.90M Share Price: $5.90

CV Sciences, Inc. (CVSI), preeminent supplier and manufacturer of phytocannabinoids including industry-leading brand, PlusCBD Oil, is pleased to announce that it will be a featured panelist at Invest Like the Pros: TheStreet’s Boot Camp for Investors, to be held on October 13, 2018 in New York City. Attendees will learn from prominent experts on various topics ranging from short-term trading strategies to the current state of the cannabis industry to the future of big tech, and more.

Important Disclaimer, Please Read:

The securities, investments, and industries referenced and impacted in the attached content, are risky investments, that can result in significant or entire loss. This article is not advice in making any speculative investment decision.

The attached content may include predictions, estimates or other information that might be considered forward-looking. While such forward-looking statements represent best judgment on what the future holds, at the time of first publishing, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on any forward-looking statements, that may be found in the attached content, as they only reflect as of the date of first publishing. Please keep in mind that authors, producers, disseminators are not obligated to revise or publicly release the results of any revision to any forward-looking statement, that may be found in the attached content, in light of new information or future events.

Regal Consulting LLC is hired by certain companies to increase awareness and disseminate material public information regarding the paying company. PPCB

expects to pay forty thousand dollars for corporate awareness services for the month of October, and expects to continue to pay Regal to disseminate truthful and potentially material information regarding PPCB.

Regal Consulting LLC is not registered with FINRA or any other financial or securities regulatory authority, and does not provide investment advice. The attached content is not investment advice. Regal Consulting LLC is not a broker dealer.

Before making investment decisions, everyone, including viewers of this content, should seek advice and perform deep and thorough research.

Regal Consulting, LLC. may buy or sell additional shares of any company named, referenced, or impacted by information in the attached content, on the open market at any time, including before, during or after the publishing of the content. The amount of stock Regal may own in PPCB can be found updated here: http://www.regalconsultingllc.com/disclaimer/.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.ACR Communication, LLC has been compensated one thousand dollars cash for this article and ninety-three thousand two hundred dollars total by Regal Consulting. LLC, for news commentary articles for PPCB.PPCB and Regal Consulting, LLC were given an opportunity to edit information included in this article.This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information.We may buy or sell additional shares of PPCB in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

For Full Legal Disclaimer Click Here.

Regal Consulting, LLC,For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspecualtors.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: ACR Communication, LLC